Autumn S Miller, | |
2230 Stockton Blvd, Sacramento, CA 95817-1353 | |
(916) 734-7251 | |
Not Available |
Full Name | Autumn S Miller |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 2230 Stockton Blvd, Sacramento, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437727468 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103T00000X | Psychologist | (* (Not Available)) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Autumn S Miller, 2230 Stockton Blvd, Sacramento, CA 95817-1353 Ph: (916) 734-7251 | Autumn S Miller, 2230 Stockton Blvd, Sacramento, CA 95817-1353 Ph: (916) 734-7251 |
News Archive
As the global market leader in human identification, Life Technologies Corporation announced today it signed a global exclusive agreement with LGC Forensics for the right to distribute ParaDNA, a portable rapid DNA system that determines the quality of human DNA faster and more economically than any existing method.
A self-directed walking program shows promise in easing joint stiffness in older women who experienced these symptoms while taking aromatase inhibitor therapy for breast cancer, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.
Crescendo Biologics today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.
Covidien today announced that on November 13, 2009, representatives of Neuromed discussed the pending New Drug Application (NDA) for the product candidate ExalgoTM (hydromorphone HCl extended release) tablets with staff from the United States Food and Drug Administration (FDA). Mallinckrodt Inc., a Covidien company, obtained the commercial rights to Exalgo in the United States from Neuromed Development Inc., a subsidiary of Neuromed Pharmaceuticals Ltd., in June 2009.
› Verified 8 days ago